Singapore markets close in 2 hours 9 minutes

Spyre Therapeutics, Inc. (AGLE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
12.01+0.75 (+6.66%)
At close: 04:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 63.65M
Enterprise value -139.95M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)58.54
Price/book (mrq)N/A
Enterprise value/revenue -132.78
Enterprise value/EBITDA 1.41

Trading information

Stock price history

Beta (5Y monthly) 2.57
52-week change 348.58%
S&P500 52-week change 311.63%
52-week high 324.00
52-week low 32.66
50-day moving average 311.52
200-day moving average 39.50

Share statistics

Avg vol (3-month) 349.05k
Avg vol (10-day) 392.05k
Shares outstanding 54.05M
Implied shares outstanding 64.05M
Float 81.92M
% held by insiders 1N/A
% held by institutions 1N/A
Shares short (14 Nov 2023) 4139.69k
Short ratio (14 Nov 2023) 43.68
Short % of float (14 Nov 2023) 43.47%
Short % of shares outstanding (14 Nov 2023) 43.45%
Shares short (prior month 12 Oct 2023) 4113.77k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:25
Last split date 307 Sept 2023

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin 0.00%
Operating margin (ttm)-9,485.01%

Management effectiveness

Return on assets (ttm)-41.82%
Return on equity (ttm)-281.41%

Income statement

Revenue (ttm)1.05M
Revenue per share (ttm)0.27
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)-262k
EBITDA -98.84M
Net income avi to common (ttm)-294.43M
Diluted EPS (ttm)-74.15
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)203.6M
Total cash per share (mrq)50.28
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)4.59
Book value per share (mrq)-60.61

Cash flow statement

Operating cash flow (ttm)-87.01M
Levered free cash flow (ttm)-2.62M